zokinvy
eigerbio europe limited - lonafarnib - progeria; laminopathies - outro aparelho digestivo e metabolismo produtos, - zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of hutchinson-gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous lmna mutation with progerin-like protein accumulation or a homozygous or compound heterozygous zmpste24 mutation.
tibsovo
les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - agentes antineoplásicos - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.
bortezomibe
sun farmacÊutica do brasil ltda - bortezomibe - antineoplasicos citotoxicos
bortyz
accord farmacÊutica ltda - bortezomibe - antineoplasicos citotoxicos
bozored
dr. reddys farmacÊutica do brasil ltda - bortezomibe - antineoplasicos citotoxicos
bortezomibe
accord farmacÊutica ltda - bortezomibe - antineoplasicos citotoxicos
mielocade
laboratÓrio quÍmico farmacÊutico bergamo ltda - bortezomibe - antineoplasicos citotoxicos
tovar
achÉ laboratÓrios farmacÊuticos s.a - bortezomibe - antineoplasicos citotoxicos
velcade
janssen-cilag farmacÊutica ltda - bortezomibe - antineoplasicos citotoxicos
zomi
sun farmacÊutica do brasil ltda - bortezomibe - antineoplasicos citotoxicos